Real‐world treatment patterns, resource use and cost burden of multiple myeloma in Portugal

Author:

Antunes Luís1ORCID,Rocha‐Gonçalves Francisco1,Chacim Sérgio1,Lefèvre Cinira2,Pereira Marta3,Pereira Sónia4,Zagorska Aleksandra2,Bento Maria José1

Affiliation:

1. Portuguese Oncology Institute of Porto (IPO-Porto) Porto Portugal

2. Bristol‐Myers Squibb Rueil Malmaison France

3. Bristol‐Myers Squibb Uxbridge UK

4. Bristol‐Myers Squibb Paço de Arcos Portugal

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Oncology

Reference14 articles.

1. Innovative agents in multiple myeloma;Faiman B.;Journal of the Advanced Practitioner in Oncology,2014

2. Age and Health Status Determine Treatment Receipt in Patients with Multiple Myeloma;Fakhri B.;Blood,2016

3. Trends in overall survival and costs of multiple myeloma, 2000–2014

4. International Agency for Research on Cancer(2012).EUCAN. Retrieved on Feb 2017 fromhttp://eco.iarc.fr/eucan/Default.aspx

5. Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3